Open AccessProspects of laboratory risk evaluation of multiple sclerosis relapse and progressing
Author(s) -
И. В. Смагина,
С. А. Ельчанинова,
А. В. Поповцева,
Ю. Н. Игнатова,
Anna Gridina,
А. С. Федянин
Publication year - 2010
Publication title -
bûlletenʹ sibirskoj mediciny
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.135
H-Index - 3
eISSN - 1819-3684
pISSN - 1682-0363
DOI - 10.20538/1682-0363-2010-4-152-155
Subject(s) - multiple sclerosis , cerebrospinal fluid , medicine , oncology , immunology
The Relapsing-Remitting Multiple Sclerosis (MS) patients research has revealed that the matrix metalloproteinase-2 level in cerebrospinal fluid which is higher then 30 ng/ml during the relapse and/or remission period increases repeated relapse risk during 2 years term by 2.8 times. The rapid MS progressing is associated with the high level of adhesion molecule (sPECAM) in cerebrospinal fluid.